FDA Unveils Program to Prioritize Review of Generic Drugs with Domestic Production
- October 10, 2025
The Food and Drug Administration (FDA) is launching a new pilot prioritization program that will expedite the review of abbreviated new drug applications (ANDA) of generic companies that test and manufacture their products in the United States.
ARTICLE TAGS
You must be logged in to access this content.